180JPY
13.97 BJPY
141.71 BJPY
34.12 M
About HISAMITSU PHARMACEUTICAL CO. INC.
Sector
Headquarters
Tosu
Founded
1847
Website
ISIN
JP3784600003
FIGI
BBG000BG6PR0
Hisamitsu Pharmaceutical Co., Inc. engages in the research, development, manufacture, and sale of pharmaceuticals and related products. Its products are sold under Salonpas, Salonsip, Mohrus, ByeBye-Fever, and Keplat brands. It also provides ethical pharmaceuticals, over- the-counter drugs, medical devices, health supplements, and topical analgesic products. The company was founded by Nihei Hisamitsu in 1847 and is headquartered in Tosu, Japan.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 4530 is 5080 JPY — it has decreased by 5.58% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NAG exchange HISAMITSU PHARMACEUTICAL CO. INC. stocks are traded under the ticker 4530.
HISAMITSU PHARMACEUTICAL CO. INC. is going to release the next earnings report on Jul 4, 2024. Keep track of upcoming events with our Earnings Calendar.
4530 stock is 5.91% volatile and has beta coefficient of 0.37. Check out the list of the most volatile stocks — is HISAMITSU PHARMACEUTICAL CO. INC. there?
4530 earnings for the last quarter are 20.46 JPY per share, whereas the estimation was 22.20 JPY resulting in a −7.84% surprise. The estimated earnings for the next quarter are 19.40 JPY per share. See more details about HISAMITSU PHARMACEUTICAL CO. INC. earnings.
HISAMITSU PHARMACEUTICAL CO. INC. revenue for the last quarter amounts to 32.10 B JPY despite the estimated figure of 31.00 B JPY. In the next quarter revenue is expected to reach 66.98 B JPY.
Yes, you can track HISAMITSU PHARMACEUTICAL CO. INC. financials in yearly and quarterly reports right on TradingView.
4530 net income for the last quarter is 1.86 B JPY, while the quarter before that showed 3.69 B JPY of net income which accounts for −49.62% change. Track more HISAMITSU PHARMACEUTICAL CO. INC. financial stats to get the full picture.
Today HISAMITSU PHARMACEUTICAL CO. INC. has the market capitalization of 286.31 B, it has increased by 1.95% over the last week.
HISAMITSU PHARMACEUTICAL CO. INC. dividend yield was 2.19% in 2023, and payout ratio reached 46.80%. The year before the numbers were 2.21% and 57.10% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, 4530 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HISAMITSU PHARMACEUTICAL CO. INC. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So HISAMITSU PHARMACEUTICAL CO. INC. technincal analysis shows the neutral today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating HISAMITSU PHARMACEUTICAL CO. INC. stock shows the neutral signal. See more of HISAMITSU PHARMACEUTICAL CO. INC. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on HISAMITSU PHARMACEUTICAL CO. INC. future price: according to them, 4530 price has a max estimate of 3950.00 JPY and a min estimate of 3950.00 JPY. Read a more detailed HISAMITSU PHARMACEUTICAL CO. INC. forecast: see what analysts think of HISAMITSU PHARMACEUTICAL CO. INC. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. HISAMITSU PHARMACEUTICAL CO. INC. EBITDA is 18.26 B JPY, and current EBITDA margin is 12.94%. See more stats in HISAMITSU PHARMACEUTICAL CO. INC. financial statements.